Immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
Melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better PFS
The future of prostate cancer therapy
Reducing late symptom reporting: a holistic approach in cancer nursing
PROSPECT: how effective is the new prostvac vaccine against prostate cancer?